Eric Benevich News Today

Bellevue Group AG trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 5.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,430,500 shares of the company’s stock after selling 153,050 shares during the period. Neurocrine […]

Sectoral Asset Management Inc. lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 10.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,445 shares of the company’s stock after buying an additional 410 shares during the period. Sectoral Asset Management […]

Wedbush reiterated their outperform rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research note published on Wednesday morning, Benzinga reports. Wedbush currently has a $152.00 target price on the stock. NBIX has been the topic of a number of other research reports. Canaccord Genuity Group lifted their price target on shares […]

Primecap Management Co. CA raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 398,323 shares of the company’s stock after acquiring an additional 6,738 shares during the period. Primecap […]

GW&K Investment Management LLC lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 535,962 shares of the company’s stock after selling 18,829 shares during the period. […]

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price increased by Oppenheimer from $200.00 to $216.00 in a research report report published on Thursday morning, Benzinga reports. The firm currently has an outperform rating on the stock. Several other equities analysts have also weighed in on the company. Wells Fargo & Company upgraded Neurocrine […]

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective hoisted by Oppenheimer from $200.00 to $216.00 in a research note issued to investors on Thursday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock. Other equities research analysts have also issued reports about the company. Citigroup reduced their price objective on […]

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price target raised by stock analysts at BMO Capital Markets from $129.00 to $138.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “market perform” rating on the stock. BMO Capital Markets’ price target would suggest a potential downside of 1.93% from […]

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective lifted by research analysts at Oppenheimer from $200.00 to $216.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s target price would suggest a potential upside of 53.51% from the stock’s previous close. […]

Certuity LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the fourth quarter, HoldingsChannel reports. The fund purchased 3,150 shares of the company’s stock, valued at approximately $415,000. Several other institutional investors and hedge funds have also bought and sold shares of the stock. Headinvest LLC purchased a new stake […]